Elizaveta A. Krekhova

Moscow, MOW 119991, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants.

Clinical and laboratory manifestations and treatment of children with TNFRSF1A gene variants.

Journal: World journal of clinical pediatrics

Published: January 27, 2026

Toward Personalized Withdrawal of TNF-α Inhibitors in Non-Systemic Juvenile Idiopathic Arthritis: Predictors of Biologic-Free Remission and Flare.

Toward Personalized Withdrawal of TNF-α Inhibitors in Non-Systemic Juvenile Idiopathic Arthritis: Predictors of Biologic-Free Remission and Flare.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: December 02, 2025

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Open-Label Phase II Study of Olokizumab in Adolescent Patients with Polyarticular Juvenile Idiopathic Arthritis: Results of the 24-Week Treatment Period.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: November 15, 2025

Can We Successfully Discontinue Anti-Tumor Necrosis Factor-α Treatment in Children with Non-Systemic Juvenile Idiopathic Arthritis? The Experience of a Tertiary Center.

Can We Successfully Discontinue Anti-Tumor Necrosis Factor-α Treatment in Children with Non-Systemic Juvenile Idiopathic Arthritis? The Experience of a Tertiary Center.

Journal: Biomedicines

Published: July 04, 2025

Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study.

Safety and Efficacy of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus Type B Infections in Children with Systemic Juvenile Idiopathic Arthritis: Prospective Cohort Study.

Journal: Vaccines

Published: April 13, 2025

The Efficacy and Safety of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus influenzae Type b Infections in Children with Juvenile Idiopathic Arthritis Without Systemic Manifestations: A Prospective Cohort Study.

The Efficacy and Safety of Simultaneous Vaccination with Polysaccharide Conjugate Vaccines Against Pneumococcal (13-Valent Vaccine) and Haemophilus influenzae Type b Infections in Children with Juvenile Idiopathic Arthritis Without Systemic Manifestations: A Prospective Cohort Study.

Journal: Vaccines

Published: January 04, 2025

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.

Safety and efficacy of canakinumab treatment for undifferentiated autoinflammatory diseases: the data of a retrospective cohort two-centered study.

Journal: Frontiers in medicine

Published: July 11, 2023

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.

Efficacy and safety of canakinumab as a second line biologic after tocilizumab treatment failure in children with systemic juvenile idiopathic arthritis: A single-centre cohort study using routinely collected health data.

Journal: Frontiers in pediatrics

Published: December 02, 2022

Showing 1-8 of 8

Last Updated: 09/26/2026